Patients with heterozygous MYBPC3 truncating variants can have a range of symptoms that develop over their life span, while patients with homozygous MYBPC3 truncating variants develop severe HF within the first year of life (52–54). The gene discussed is MYBPC3; the disease is hydrops fetalis.